GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CinCor Pharma Inc (NAS:CINC) » Definitions » Profitability Rank

CinCor Pharma (CinCor Pharma) Profitability Rank : 1 (As of Sep. 2022)


View and export this data going back to 2022. Start your Free Trial

What is CinCor Pharma Profitability Rank?

CinCor Pharma has the Profitability Rank of 1. It has had trouble to make a profit.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

CinCor Pharma's Operating Margin % for the quarter that ended in Sep. 2022 was %. As of today, CinCor Pharma's Piotroski F-Score is 9999.


Competitive Comparison of CinCor Pharma's Profitability Rank

For the Biotechnology subindustry, CinCor Pharma's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CinCor Pharma's Profitability Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CinCor Pharma's Profitability Rank distribution charts can be found below:

* The bar in red indicates where CinCor Pharma's Profitability Rank falls into.



CinCor Pharma Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

CinCor Pharma has the Profitability Rank of 1. It has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

CinCor Pharma's Operating Margin % for the quarter that ended in Sep. 2022 is calculated as:

Operating Margin %=Operating Income (Q: Sep. 2022 ) / Revenue (Q: Sep. 2022 )
=-22.244 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

CinCor Pharma has an F-score of 9999. It is a bad or low score, which usually implies poor business operation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


CinCor Pharma Profitability Rank Related Terms

Thank you for viewing the detailed overview of CinCor Pharma's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


CinCor Pharma (CinCor Pharma) Business Description

Traded in Other Exchanges
N/A
Address
200 Clarendon Street, 6th Floor, Boston, MA, USA, 02116
CinCor Pharma Inc is a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases.
Executives
Sofinnova Management X-a, L.l.c. 10 percent owner 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
James Healy director, 10 percent owner 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Michael Wayne Kalb officer: EVP & Chief Financial Officer 24 LUCILLE LANE, DIX HILLS NY 11746
5am Opportunities Ii (gp), Llc 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISO CA 94107
5am Opportunities Ii, L.p. 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Partners Vi, Llc 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Partners Sas Sofinnova 10 percent owner 17 RUE DE SERENE, PARIS I0 75008
Maha Katabi 10 percent owner SOFINNOVA INVESTMENTS, 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Sofinnova Venture Partners X, L.p. 10 percent owner 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Sofinnova Management X, L.l.c. 10 percent owner 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
General Atlantic Genpar (bermuda), L.p. 10 percent owner C/O GENERAL ATLANTIC SERVICE COMPANY,LLC, 55 EAST 52ND ST. 32ND FLOOR, NEW YORK NY 10055
General Atlantic, L.p. 10 percent owner 55 EAST 52ND STREET, 33RD FLOOR, NEW YORK NY 10055
Mason Freeman officer: EVP Clinical Development C/O CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO CA 92121
Mary Theresa Coelho officer: EVP CFO & Chief BD Officer 52 SUNRISE PARK ROAD, NEW HAMPTON NY 43017
Garidel Marc De director, officer: Chief Executive Officer C/O CINCOR PHARMA, INC., 200 CLARENDON STREET, 6TH FLOOR, BOSTON MA 02116

CinCor Pharma (CinCor Pharma) Headlines

From GuruFocus

CinCor Pharma to be Acquired by AstraZeneca

By Stock market mentor Stock market mentor 01-09-2023